Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.
Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2'-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.
Coelmont
Lotte
L
Rega Institute for Medical Research, KULeuven, Leuven, Belgium.
Paeshuyse
Jan
J
Windisch
Marc P
MP
De Clercq
Erik
E
Bartenschlager
Ralf
R
Neyts
Johan
J
D000998:Antiviral Agents / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003562:Cytidine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D004336:Drug Antagonism; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D012254:Ribavirin / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; C513402:2'-C-methylcytidine; D012254:Ribavirin; D003562:Cytidine